

FOR UK HEALTHCARE PROFESSIONALS ONLY

PRESS RELEASE

**Aspire adds to their Respiratory Portfolio to Build on their
Strategic Commitment**

Petersfield, Hampshire, 18 March 2024: Aspire Pharma Limited today announced the addition of Fluticasone propionate 400mcg (1mg/ml) nasal drops, suspension x 30 to their respiratory portfolio. This addition further establishes Aspire as a premier specialty generics business.

This follows a recent discontinuation of fluticasone nasal drops by another manufacturer leading to a possible short supply for patients.¹

Fluticasone is indicated for the regular treatment of nasal polyps and associated symptoms of nasal obstruction in adolescents and adults over 16 years of age.² The product is available in packs of 30 single dose containers, each containing 400mcg of fluticasone propionate, equating to 1mg/ml.² The use of fluticasone can help reduce swelling and the need for surgical intervention or rescue medication (i.e. oral steroids).³

A nasal polyp is a swelling of the lining of the nose, which is usually due to inflammation of the lining of the nose and are often ignored by people assuming it to be a boil or any common infection. When these nasal polyps are left untreated, they can develop serious health conditions like obstructive sleep apnoea, asthma flare-ups, and sinus infection.⁴

Nasal polyps are more common in men (up to 4:1) yet in those who have late onset asthma, it can also occur in women. The chance of developing nasal polyps is between one and 20 for every 1,000 people and after the age of 60 the chance of developing polyps declines. Polyps respond and shrink using drops or sprays in up to 80% of people.³

References

¹Direct Healthcare Professional Communication: Fluticasone Propionate (Flixonase) Nasule 400 micrograms (1 mg/ml) Nasal Drops Suspension: Permanent Discontinuation Notification, GOV.UK. Available at: https://assets.publishing.service.gov.uk/media/64998b4dde8682000cbc8de3/Fluticasone_Propionate.pdf (Last accessed March 2024)

² Fluticasone propionate 400 micrograms (1mg/ml), nasal drops suspension, Electronic Medicines Compendium. Available at: <https://www.medicines.org.uk/emc/product/14919/smpc#gref> (Last accessed March 2024)

³ Nasal Polyps – Under Review, ENTUK. Available at: https://www.entuk.org/patients/conditions/41/nasal_polyps_under_review/ (Last accessed March 2024)

⁴ What Happens if Nasal Polyps Go Untreated, MedicineNet. Available at: https://www.medicinenet.com/what_happens_if_nasal_polyps_go_untreated/article.htm (Last accessed March 2024)

10105772210 v1.0 March 2024

Prescribing information is available [here](#)

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148.

<Ends>

Note to Editor

About Aspire Pharma

Aspire was established with a simple mission: *To make a difference to the lives of patients through the development and supply of innovative products and medicines throughout the world.* Aspire is present in the generics, niche generics, branded medicines, and medical device sectors. Aspire was majority acquired by an affiliate of H.I.G. Capital (“H.I.G.”) in 2021. For more information, go to www.aspirepharma.co.uk

H.I.G. Capital is a leading global private investment firm with \$60 billion* of capital under management. The H.I.G. family of funds includes private equity, growth equity, real estate, direct lending, infrastructure, and biohealth. We align ourselves with committed management teams and entrepreneurs and help build businesses of significant value. For more information, visit hig.com

*Based on total capital commitments managed by H.I.G. Capital and affiliates.

Media Contact

Email: pressoffice@aspirepharma.com

Tel: +44 1730 231148